Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clinical applicability and accuracy of a population pharmacokinetic model for individualized vancomycin dosing
ChiCTR2500100014Phase 4Not yet recruiting
- Sponsor
- Suqian People's Hospital
- Start
- Apr 2025
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of vancomycin in Infectious disease (3 arms), sponsored by Suqian People's Hospital. Primary endpoints: prediction error and mean absolute percentage error (MAPE). Planned start Apr 2025; status: not yet recruiting.
02
Drugs
vancomycin
03
Conditions
Infectious disease
Beyond the preview
Go deeper on ChiCTR2500100014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100014.